Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

Article Title and Bibliographic Information

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

Grbic JT, et al.

J Am Dent Assoc 2008;139(1):32-40.

Level of Evidence

Level 3: Other evidence.

Strength Of Recommendation Grade

Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening.

Purpose/Question

What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid?

Source of Funding

Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study.

Type of Study/Design

Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.